ABL1 and acute lymphoblastic leukemia: Double positivity for CD66c+/CD73+ (56.9% vs. 94.0%), CD66c+/CD304+ (6.9% vs. 58.8%), and CD73+/CD304+ (15.5% vs. 75.5%) was significantly lower in non-Ph+ B-ALL patients compared to BCR::ABL1-positive B-ALL patients (p < 0.001).